ECCO’27 (22nd ECCO Congress)
March 3–6, 2027 | Bella Center, Copenhagen, Denmark
If your IBD program needs predictable enrollment and reliable site execution, meet PSI CRO at ECCO’27 to see how your feasibility assumptions stack up against what sites can truly deliver.
What sponsors can expect from a conversation with PSI CRO at ECCO’27
ECCO’27 is your chance to pressure-test your ulcerative colitis and Crohn’s disease trial plans against real-world site capacity, country start-up timelines, and competing-study dynamics. PSI brings deep IBD execution experience, supporting 35% of all industry-sponsored UC trials and delivering enrollment rates over 50% higher than the industry average in IBD programs.
Our discussions with sponsors will focus on the operational decisions that most often determine whether timelines stay on track:
- Country and site strategy aligned to current ECCO community insights and active pipeline congestion
- Start-up readiness (EC/IRB pathways, contract/budget cycle times, essential document velocity)
- Realistic enrollment and retention expectations based on indication-specific site performance and patient journey challenges
- Data quality and inspection readiness integrated into daily monitoring and site support
Stop by to discuss practical enrollment scenarios and site activation plans for IBD studies, including how PSI uses SYNETIC™ site intelligence to identify IBD-experienced institutions and reduce unnecessary feasibility churn.
Related resources:
White paper: Placebo response in IBD trials- PSI CRO
Blog: Advances in IBD treatment considerations, GI trial design, and the impact of AI
Case Study: Managing enrollment and site performance in competitive upper GI trial programs
Webinar: Agentic AI in Clinical Trials — Swiss Biotech Day Panel
White Paper: The operational reality of agentic AI in phase 2-3 trials
